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AbstrACt
Objectives Recent studies in referred populations of 
patients with superficial venous thrombosis (SVT) report 
risks of venous thromboembolic (VTE) sequelae (deep 
vein thrombosis or pulmonary embolism) as high as 25%. 
Likely, these estimates are lower in non-referred patients, 
but large-scale population-based studies are lacking. We 
aimed to estimate the incidence rate of SVT in primary 
care and quantify its risk of VTE sequelae.
Design A retrospective cohort study, using International 
Classification of Primary Care coding (K94.02) combined 
with free text searching (synonyms for SVT) to capture all 
SVT events. All patients were followed up for 3 months 
using manual free text searching.
setting Primary care.
Participants All patients enlisted with general 
practitioners within the Utrecht General Practitioner 
Network between 2010 and 2016 (1 534 845 person-
years follow-up).
Main outcome measures The incidence rate of SVT was 
expressed as the number of SVT events per 1000 person-
years of follow-up and the 3-month cumulative incidence 
of VTE events was calculated. Logistic regression analysis 
was used to compare patients with SVT with and without 
VTE sequelae.
results A total of 2008 SVT cases were identified, that is, 
an SVT incidence rate of 1.31 (95% CI 1.25 to 1.37) per 
1000 person-years follow-up, with higher rates notably 
with increasing age. VTE sequelae occurred in 83 patients; 
51 at the time of SVT diagnosis and 32 patients during 
follow-up (total cumulative incidence of 4.1%; 95% CI 
3.3% to 5.1%), and were more frequent in those with an 
active malignancy (OR 2.19; 95% 0.97 to 4.95) and less 
frequent in those with varicose veins at baseline (OR 0.57, 
95% CI 0.34 to 0.94).
Conclusion We found an incidence rate of SVT in primary 
care of 1.31 per 1000 person-years. The risks of VTE 
sequelae was relatively low at 4.1%, with the highest risk 
in patients with cancer and in those who experience an 
SVT in the absence of varicose veins.
IntrODuCtIOn
Superficial thrombophlebitis—or superficial 
venous thrombosis (SVT)—is a local non-in-
fectious inflammation of a superficial vein, 
caused by a thrombus. The diagnosis is usually 
based on clinical signs and symptoms—that 
is, a red, tender, swollen and palpable area 
along the course of a superficial vein—with 
confirmation on leg ultrasonography where 
needed. It has generally been regarded as a 
relatively benign and self-limiting disease. 
Recently, however, there is a growing atten-
tion to its associated venous thromboembolic 
(VTE) risk such as deep vein thrombosis 
(DVT) or pulmonary embolism (PE). For 
instance, a recent systematic review reported 
a weighted mean prevalence of concurrent 
DVT of 18.1% (95% CI 13.9% to 23.3%) and 
strengths and limitations of this study
 ► A limitation of this study is its retrospective nature, 
and thus the inability to fully adjust for provided anti-
coagulant treatment (although provided in a minority 
of patients) as well as lack of detailed information 
regarding superficial venous thrombosis (SVT) loca-
tion (notably involvement of saphenofemoral junc-
tion) or imaging confirmation of (length of) SVT in all 
study patients.
 ► A potential advantage of our study is that—by ad-
dressing this research question in primary care—
we bypassed the effect that patients with SVT that 
appear in research performed in secondary care are 
sicker or more likely to have an increased risk of 
thromboembolic sequelae.
 ► Thereby, our findings may reflect the burden of SVT 
in terms of thromboembolic risk more as present in 
the community care setting.
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6.9% (95% CI 3.9% to 11.8%) for concurrent PE at SVT 
diagnosis.1 Also, the risk of propagation to DVT or PE in 
the 3 months following SVT diagnosis may be substantial, 
with reported estimates of at least 15%.2–4 Not surpris-
ingly, treatment with anticoagulation—either parentally 
(eg, fondaparinux) or orally (eg, rivaroxaban)—has been 
evaluated in randomised trials, with beneficial effects on 
reducing the risk of thromboembolic sequelae.5 6 
Most studies on SVT risk and management, however, 
have been performed in selected, referred populations 
in a secondary healthcare setting. The limited number of 
studies performed in non-selected populations report a 
much lower risk of around 2.5% for propagation to DVT or 
PE after SVT diagnosis.7 8 Differences in casemix between 
referred and non-selected patients with SVT are likely to 
contribute to these conflicting findings. In fact, in the 
aforementioned review of Di Minno et al, DVT presence 
at the time of SVT diagnosis ranged from 3.1% to 65.6% 
with higher prevalence in selected or referred popula-
tions.9 10 Studies performed in non-selected patients were 
few, relatively small (including less then 200 patients) or 
reported little if any information on patient characteris-
tics or prescribed treatment. Nevertheless, many (if not 
most) patients with SVT are first assessed and managed in 
primary or community care. Only a small selection, most 
likely the more severe cases, is referred to secondary care. 
Given that most current studies were performed in highly 
selected patient samples, the actual incidence of SVT in a 
community care setting remains unknown. Knowledge on 
thromboembolic risks in non-selected patients with SVT 
and identification of subgroups of patients with SVT at 
highest risk is needed to facilitate evidence-based antico-
agulant treatment decisions for patients with SVT.
The objectives of this study were to quantify (1) the 
incidence rate (IR) of SVT in the community, (2) the 
short-term thromboembolic risks in these non-selected 
patients with SVT—both in terms of concurrent presence 
and propagation to DVT or PE. Finally, (3) we aimed to 
identify patient subgroups with the highest risk of VTE.
MethODs
setting and participants
This study was conducted using healthcare data from 
the Utrecht General Practitioner Network database. 
This database contains anonymous routine healthcare 
data extracted from the electronic medical record 
(EMR) of 140 general practices in Utrecht and vicinity. 
The practice centres contributing to the database 
represent the average Dutch urban population.11 The 
general practitioners (GPs) working in the centres 
are trained in correct disease coding (using the codes 
from the International Classification of Primary Care, 
ICPC) and have experience in EMR use and coding for 
Figure 1 Flow chart of included patients. DVT, deep vein thrombosis; PE, pulmonary embolism; SVT, superficial venous 
thrombosis; VTE, venous thromboembolism.
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an average period of 10 years. In the Netherlands, all 
citizens are registered with a GP, irrespective of cooper-
ative care from a medical specialist, including patients 
living in a home for the elderly, but with the exception 
of those living in a nursing home or hospice. This study 
population is therefore a representative and complete 
sample of people from the community.
study design and assessment of sVt and Vte
Using this database, all patient contacts with their 
GP were retrieved for the period 2010–2016 to detect 
new diagnoses of SVT, that is, 1 534 845 person-years 
follow-up. The EMRs were automatically scrutinised for 
the ICPC code of SVT (K94.02) in addition to auto-
mated ‘free text searching’ in all patient contacts using 
a variety of synonyms for SVT. SVT was deemed present 
if the GP clearly described signs and symptoms related 
to a new SVT diagnosis (typically red, tender, swollen 
and palpable area along the course of a superficial 
vein with or without a confirmation of the ICPC code 
K94.02). Patients were excluded if (1) such findings 
were not clearly reported leading to uncertainty of the 
SVT diagnosis; (2) SVT was only considered in differ-
ential diagnosis but finally ‘ruled-out’ (not managed 
accordingly) by the GP and/or (3) SVT was part of 
a patients’ medical history rather than related to 
current and new complaints. Next, in all patients with 
a confirmed SVT diagnosis using our definitions, the 
following baseline characteristics were collected: age, 
gender, a history of cardiac and pulmonary diseases, 
diabetes, and the presence or absence of active malig-
nancy, varicose veins or pregnancy at the time of the 
clinical assessment.
After confirmation of an SVT diagnosis (as described 
above), we first assessed the presence (or absence) of 
concurrent DVT or PE at the time of SVT diagnosis, 
with concurrent presence defined as (1) the presence 
of imaging findings suggestive for DVT or PE at the 
same consultation, or within 7 days following SVT diag-
nosis, reported in the free text and/or (2) clinically, 
if in the free text initiation of low-molecular-weight 
heparin (LMWH) combined with a vitamin K antag-
onist was described (which we considered the conse-
quence of a DVT or PE diagnosis).
Each patient was followed by scrutinising all subse-
quent patient contacts in the 3 months following the 
SVT diagnosis, using manual free text searching. The 
following outcomes were collected: (1) subsequent 
management, consisting of either (a) watchful waiting 
with or without supportive measures like topical treat-
ment or stockings or (b) LMWH and (2) the occur-
rence of propagation to DVT or PE (same definitions as 
for DVT/PE presence at SVT diagnosis). If in the EMR 
propagation to DVT and/or PE was never mentioned 
or considered during these 3 months of follow-up, we 
deemed such propagation as absent. As such, there was 
(strictly speaking) no missing data as we deemed DVT 
and/or PE absent in case it was not recorded in the 
EMR.
sample size considerations
Given the retrospective nature of this study, no formal 
statistical sample size calculation was performed prior 
to the start of this study. Instead, the aim of this study was 
to capture and describe all patients with SVT currently 
diagnosed in a community-dwelling setting. Neverthe-
less, with an estimated IR for SVT of around 1.5 per 
1000 person-years of follow-up (although highly uncer-
tain prior to the initiation of this study), we anticipated 
to include around 360 SVTs per year (~240 000 person-
years of follow-up annually), leading to a possible total 
number of around 2160 patients with SVT.
Figure 2 Incidence rate of superficial venous thrombosis according to age. IR, incidence rate.
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statistical analyses
The IR of SVT was expressed as the number of SVT 
events per 1000 person-years of follow-up, and a 95% CI 
was calculated. We stratified these analyses for different 
age categories and gender. Next, we calculated the 
3-month cumulative incidence of VTE sequelae using 
our above-described definitions. As an explorative anal-
ysis, using logistic regression, we compared SVT with 
and without DVT and/or PE sequelae either at the 
time of SVT diagnosis or during 3 months follow-up, 
including an OR (plus a corresponding 95% CI). Based 
on previous studies in the field, the following five base-
line patient characteristics were assessed: age (dichoto-
mised at 75 years), gender, active malignancy (defined 
as an active treatment provided within the 3 months 
prior to SVT diagnosis or malignancy with metastasis 
leading to palliative care), varicose veins and preg-
nancy. The predictive capacity of these five covariates 
for the occurence of VTE sequelae was assessed into 
the logistic model both univariately as multivariately, 
thus without a selection of covariates into the multivar-
iate model based on p values. All data were analysed 
using SPSS V.21.0 (SPSS).
ethics statement
The study received a waiver for formal reviewing. As such, 
according to Dutch law, no explicit informed consent was 
required as data reducible to the patients were only avail-
able at the GP practices and were made anonymous for 
data evaluation and analysis by the researchers.
Patient involvement
Given the retrospective nature of this study, no patients 
were involved during this study.
results
In total, we identified 2008 patients with SVT during 
the 6-year period, corresponding with an SVT IR of 
1.31 (95% CI 1.25 to 1.37) per 1000 person-years (see 
figure 1). The mean age of all patients with SVT was 56 
years, and 66% were female. In males, the IR was slightly 
lower as compared with females, that is, 1.16 (95% CI 
1.01 to 1.24) vs 1.67 (95% CI 1.58 to 1.76). We observed 
an increasing IR with increasing age, ranging from 0.73 
(95% CI 0.66 to 0.79) in patients below 40 years of age to 
2.95 (95% CI 2.56 to 3.38) in patients above 80 years of 
age (see figure 2). Fifty-one patients (prevalence of 2.5%; 
95% CI 1.9% to 3.3%) had a VTE (50 DVT and 1 PE) at 
inclusion, whereas in the remaining 1957 patients free of 
VTE after 1 week 32 patients (incidence of 1.6%; 95% CI 
1.2% to 2.3%) experienced propagation to VTE within 
3 months of follow-up (20 DVT and 12 PE; median time 
to propagation was 36 days). Thus, in total, VTE events 
were observed in 83 patients, leading to a cumulative inci-
dence of 4.1% (95% CI 3.3% to 5.1%).
As compared with patients with SVT without VTE 
events, only absence of varicose veins and presence of 
an active malignancy were associated with VTE sequelae 
during 3 months of follow-up in patients with SVT (see 
table 1). LMWH was provided in the minority of patients 
(n=146, 7.3%). In most patients, a watchful waiting 
approach—which could include over-the-counter pain 
medication—was applied, with or without stockings or 
topical treatment (table 2).
DIsCussIOn
In this large community-based cohort study, the observed 
SVT IR was around 1.3 cases per 1000 person-years. IR’s 
were higher in women and more notably increased with 
increasing age, with the highest rate of nearly 3 cases per 
1000 person-years in elderly patients above 80 years of 
age. Most patients (>90%) were treated conservatively, 
thus without the initiation of anticoagulant treatment. 
The risk of (subsequent) VTE sequelae was relatively 
low at around 4% during 3 months of follow-up, and 
in the majority of those patients (~60%), VTE sequelae 
Table 1 Characteristics of included patients with SVT
Item Isolated SVT n/N (%)
SVT with VTE sequelae 
n/N (%)
OR (95% CI)
Univariate Multivariate
Age
  Mean age 56.3 years 56.2 years NA NA
  Proportion >75 years 371/1925 (19.3%) 13/83 (15.7%) 0.78 (0.43 to 1.42) 0.76 (0.41 to 1.40)
Females 1271/1925 (66.0%) 52/83 (62.7%) 0.86 (0.55 to 1.36) 0.99 (0.62 to 1.57)
Active malignancy 74/1925 (3.8%) 7/83 (8.4%) 2.30 (1.03 to 5.17) 2.19 (0.97 to 4.95)
Pregnancy 82/1925 (4.3%) 1/83 (1.2%) 0.27 (0.04 to 1.99) 0.28 (0.04 to 2.05)
Varicose veins 760/1925 (39.5%) 22/83 (26.5%) 0.55 (0.34 to 0.91) 0.57 (0.34 to 0.94)
NA, not applicable; SVT, superficial venous thrombosis; VTE, venous thromboembolism.
Table 2 Provided treatment strategies in patients with 
superficial venous thrombosis in primary care
Item n/N (%)
Low molecular weight heparin 146/2008 (7.3%)
Stockings 516/2008 (25.7%)
Topical treatment 240/2008 (12.0%)
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occurred either directly at the time of SVT diagnosis or 
within 7 days. In the remainder of patients in whom prop-
agation after 7 days was present, this occurred at a median 
follow-up of 36 days, indicating that in fact the risks of 
VTE sequelae (either concurrent presence or propaga-
tion) are predominantly present in the first month after 
SVT diagnosis. Active malignancy and absence of varicose 
veins were significantly more common in patient with 
SVT with than in those without VTE sequelae.
Comparison with existing literature
The true IR of SVT in a community care setting has long 
been unknown. Recently, Frappé et al published the results 
from the STEPH study.9 They used a rigorous approach, 
inviting all primary care physicians and vascular surgeons 
in the Saint-Etienne region (catchment area 265 687 
adults) to refer (between November 2011 and November 
2012) all suspected SVT cases for compression ultraso-
nography. Their analyses included 171 confirmed SVT 
cases in that year, leading to an IR of 0.64 SVT cases per 
1000 person-years (95% CI 0.55 to 0.74), thus around 
half the rate of our current study. Their analyses, were, 
however, still based on hospital-confirmed SVT diagnoses 
and thereby depending on the willingness of primary 
care physicians to refer all (suspected) patients with SVT 
to the hospital. This is likely to lead to an underestima-
tion of the true IR in the community, as likely primary 
care physicians (only) refer the more severe SVT cases to 
the hospital. There is indeed a suggestion in their data 
that this is what happened: the median age was 68 years 
and over 80% had varicose veins, whereas these numbers 
were 56 years and less than 40% in our study. Similarly, 
the proportion of patients with concurrent DVT at the 
time of SVT diagnosis was 24.6%, that is, much higher 
than in our study. We, therefore, believe that the findings 
of our study (1.31 SVT cases per 1000 person-years) more 
truly reflect the IR of SVT in the community care setting.
Our findings indicate a lower risk of VTE sequelae 
as compared with the available observational evidence 
suggesting that VTE risk may be as high as 25%. These 
studies, however, likely reflect (highly) selected samples 
of patients with SVT with inclusion into these datasets 
based on referral and thus a selection on SVT severity.1–4 
Likely, our sample of patients with SVT more reflects 
findings from a non-referred, community based and thus 
less severe population of SVT cases. This phenomenon is 
called the ‘iatrotropic stimulus’ and essentially underpins 
the need to perform research in a primary care setting, 
in order to test if replication of observations made in 
referred, more severe populations whether or not hold 
in primary care medicine.12 Interestingly, if we compare 
our findings with the VTE risks in the placebo group in 
the (by far) largest SVT trial up to date (Comparison of 
Arixtra in Lower Limb Superficial Vein Thrombosis with 
Placebo (CALISTO))—comparing fondaparinux 2.5 mg 
once daily with placebo—we observe rather similar find-
ings. The composite of VTE-related risks (ie, death, symp-
tomatic DVT or PE, symptomatic propagation to the 
saphenofemoral junction (SFJ), or symptomatic recur-
rent SVT) occurred in 88 out of 1500 (placebo) patients 
during 47 days of follow-up, that is, 5.9%.6 This propor-
tion is only slightly higher than our finding of 4.1%, 
which might be explained by the inclusion of SFJ involve-
ment into their primary outcome which we obviously, due 
to the retrospective nature of our study, were unable to 
include. In addition, some of our patients (7.3%) were 
treated with LMWH, and thus likely experience a lower 
risk of such events.
Compared with the available secondary care-based 
studies, we observed a lower cumulative VTE incidence 
in community care-based patients with SVT. Yet, our find-
ings of a higher VTE risk in patients with cancer with SVT 
and a lower risk in patients with concurrent varicose veins 
are largely in accordance with existing literature. For 
instance, one of the largest secondary care-based study 
in this field (the Prospective Observational Superficial 
Thrombophlebitis study, n=844), also found a history 
of cancer and absence of varicose veins to be associ-
ated with a higher risk of VTE propagation in patients 
with SVT.2 Similarly, in the Multiple Environmental and 
Genetic Assessment VTE case–control study, the overall 
odds of VTE after SVT was 5.5-fold (95% CI 4.4 to 6.8) 
increased, whereas in patients with a strong thromboem-
bolic risk factor—notably including malignancy—this 
increase was 34.9-fold (95% CI 19.1 to 63.8).13 Finally, 
Baggen et al found in a systematic review including six 
studies (total number of SVT patients, n=1938) that in 
five of these six studies absence of varicose veins was asso-
ciated with a higher prevalence of concurrent DVT at 
the time of SVT diagnosis (prevalence range 33%–44% 
vs 3%–23%, in patients without and with varicose veins, 
respectively).14 Nevertheless, although largely in accor-
dance with existing literature, we would like to stress that 
our observations from the underlying logistic models (as 
presented in table 1) should be regarded as an explor-
atory analysis, simply due to the fact that our retrospective 
design prevents us from assessing the predictive impor-
tance of all relevant variables.
strengths and limitations
Strengths of our study include a large community, 
primary care-based cohort using a rigorous approach of 
‘free text’ searching in order to capture all SVT cases as 
well as its VTE sequelae during 3 months of follow-up. 
However, for full appreciation the following limitations 
need to addressed.
First, we used a retrospective design. Thus, inherently 
to this design, there always is a risk of not capturing all 
SVT events and their subsequent VTE sequelae. The 
previously referenced recent systematic review on VTE 
presence at the time of SVT diagnosis indeed reported 
a lower weighted mean DVT prevalence of 10.0% (95% 
CI 5.6% to 17.2%) in the retrospective studies compared 
with the overall mean weighted prevalence of 18.1% 
(95% CI 13.9% to 23.3%). This indeed may indicate 
that a retrospective design may underestimate VTE risk. 
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These retrospective studies also differed from prospective 
studies in the type of patients included. For instance, inpa-
tients (who are at highest VTE risk) were not included in 
the retrospective studies, whereas they were included in 6 
out of the 14 prospective studies. Also, having a retrospec-
tive design limited us in identifying some subgroups of 
patients with SVT at increased subsequent VTE risk, such 
as those with a specific extent or location of SVT, those 
with a history of VTE or specific other sites of SVT such 
as Mondor disease or upper limb SVT. It is for instance 
widely appreciated that SVT cases with SFJ involvement 
are more prone to progress to DVT.1 Nor were we able to 
ascertain if a confirmed SVT diagnosis based on our defi-
nition was the patients’ first lifetime event, as we cannot 
completely rely that this is routinely reported in medical 
files. However, a potential advantage of the retrospective 
nature of our study performed in primary care is that (by 
design) we were more likely able to capture all SVT cases. 
Studies performed in a secondary care setting may depen-
dent on the willingness of primary care physicians to refer 
patients to a vascular centre in order to include them in 
their dataset. This effect—called the ‘iatrotropic stim-
ulus’ or ‘interiatric referral’—affects the likelihood that 
patients appear in a specific setting in which the research 
questions is addressed.12 By performing our research in 
primary care, we consequently were able to (finally) truly 
estimate the IR of SVT in the community.
Second, an important aspect of our study is that due to 
the observational aspect of our study part of the patients 
(ie, 7.3%) were managed with anticoagulant treatment. 
Although still a minority, this obviously will lower the risk 
of VTE sequelae after SVT diagnosis, thus possibly under-
estimating our estimates for VTE risk.
Third, we only manually extracted follow-up informa-
tion of 3 months after SVT diagnosis. Likely, a longer 
follow-up period would have yielded more VTE sequelae. 
Nevertheless, these 3 months of follow-up is in accordance 
with previous studies in the field, importantly as the risk 
of subsequent VTE sequelae is highest in these first 3 
months.8 Moreover, indeed, our analyses clearly conform 
that in fact the risk of VTE is highest in the first month after 
SVT diagnosis. Moreover, given the retrospective nature 
of our study, patients were not routinely contacted at 3 
months to ascertain if a VTE event occurred. As such, we 
cannot completely rule-out the possibility that not all VTE 
outcome events are captured as we had to rely on informa-
tion as reported within the electronic medical files. Thus, 
this could lead to an underestimation of the proportion 
of patients with a VTE outcome, for example, if a patient 
with a VTE outcome directly went to the hospital without 
a consultation with the GP first. However, in the Nether-
lands, all patients are registered with a GP and all hospital 
discharge information is routinely collected and reported 
within Utrecht General Practitioner Network. Hence, we 
expect that this underestimation likely is negligibly small.
Fourth, this was a practice-based study in a primary 
healthcare setting, and as such not all patients under-
went formal confirmation of the SVT diagnosis using 
ultrasonography. On a similar level, the presence or 
absence of varicose veins was based on clinical grounds as 
reported by participating GPs within the Utrecht General 
Practitioner Network. Finally, also the identification of 
subsequent VTE sequelae was based on signs and symp-
toms first, with only confirmation in those with sugges-
tive symptoms during 3 months of follow-up. Although 
following clinical practice and patient management, all 
this may result in some form of misclassification of events 
and patient characteristics. However, participating GPs 
within our network are experienced in classifying patient 
contacts as accurate as possible for research purposes for 
an average period of 10 years, and we successfully used 
this database for thrombosis research, for example, for 
quantifying patient and doctor delay when diagnosing 
PE.15
Implications for clinical practice and future studies
When a patient is diagnosed with SVT in a primary care 
setting, logically, the next important question will be: do 
we need to anticoagulant this patient in order to prevent 
subsequent VTE sequelae and how is this risk reduction 
weighted against the inherent risk of bleeds related to this 
treatment? This answer will obviously not be answered by 
our observational retrospective study. In the largest place-
bo-controlled randomised trial on SVT management—
the CALISTO trial—fondaparinux prescribed for 45 
days reduced the risk of VTE sequelae with a relative risk 
reduction of 0.15 (95% CI 0.04 to 0.50) as compared with 
placebo, without an increase in the risk of major bleeding 
complications (only 0.1% in both groups).6 More 
recently, the direct oral factor Xa inhibitor rivaroxaban 
was shown to be non-inferior to fondaparinux, although 
in a relatively small study (certainly when compared with 
the CALISTO trial).5 Importantly though, as mentioned 
earlier, our observed risk of VTE sequelae of around 4% 
is actually more or less comparable to the risk of VTE 
sequelae in the placebo group from the CALISTO trial. 
Also, the latest guideline on VTE prophylaxis in surgical 
patients recommends anticoagulant prophylaxis in those 
at intermediate (~3%) or high risk (~6%), depending on 
bleeding risk.16 Thus, this may indicate that indeed we do 
need to treat patients with SVT with anticoagulants, given 
the substantial risk reduction on VTE sequelae of around 
85% while on anticoagulants with no apparent increase 
in major bleeding risk. However, we need to appreciate 
that most patients with SVT actually carry a very low risk 
of VTE sequelae. Similarly, we surely do not consider anti-
coagulant treatment in patients suspected of DVT, where 
the overall prevalence of DVT at 3 months is around 10%. 
Hence, the absolute benefit that patients will get from 
anticoagulant treatment likely will be greater in those at 
a higher risk of VTE sequelae.17 Stratified approaches, 
that is, separating those at higher risk of VTE from the 
low-risk population, may be the next step in order to 
optimise cost-effectiveness and the benefit–harm rela-
tion from anticoagulants. Ideally, therefore, further risk 
stratification of patients with SVT (both in terms of VTE 
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risk and bleeding risk on anticoagulant treatment) is 
important and similar, large, population-based studies like 
ours (where we identified a cancer diagnosis and absence 
of varicose veins as VTE risk indicators) are required to 
guide treatment decisions in daily practice. In addition to 
this—which is in agreement with the latest guidance from 
Cochrane—other outcomes like quality of life and costs 
then should also be assessed, preferably in randomised 
controlled trials on anticoagulant treatment in SVT.18
COnClusIOns
In this largest community-based cohort study to date, we 
observed an IR for SVT of around 1.3 new cases per 1000 
person-years. The risk of subsequent VTE sequelae was 
relatively low at 4.1%, and these risks likely are highest 
in the first month after SVT diagnosis and occur more 
often in patients with cancer and in those who experience 
an SVT in the absence of varicose veins. Future studies 
are warranted to risk-stratify patients with SVT in order 
to tailor anticoagulant treatment to those at highest risk 
of VTE.
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